No Data
Collplant Announces Six-Month Study Data From Its Regenerative Breast Implant Program & That It Recently Received A $2M Development Payment From Abbvie
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
BOCOM INTL: Raised SIMCERE PHARMA's Target Price to HKD 11.2 and continues to select the company as a key recommended symbol in the Industry.
BOCOM INTL released a Research Report stating an increase in the adjusted Net income forecast for SIMCERE PHARMA (02096) for 2025-26 by 6-8%, primarily reflecting a more optimistic outlook for profit margin improvement. The report indicates that the company's performance growth is expected to recover as scheduled in 2H24, and this trend is anticipated to continue into 2025-27, with six Innovative Drugs expected to be launched. Additionally, the innovative technology platform is likely to continue generating opportunities for BD overseas. The Target Price has been raised to HKD 11.2, corresponding to a PE of 22 times for 2025E and a 1.1 times 2025E PEG (based on 2024-27E adjusted Net income CAGR), Bullish.
CICC: Maintained SIMCERE PHARMA's rating of outperforming the Industry, Target Price 8.80 Hong Kong dollars.
CICC released a research report stating that the profit forecasts for 2025 and 2026 are largely unchanged, maintaining SIMCERE PHARMA (02096) as outperforming the industry rating with a Target Price of 8.80 Hong Kong dollars, corresponding to a PE of 17.4 times for 2025 and 15.6 times for 2026. The company announced that its 2024 performance meets market expectations, with revenue of 6.635 billion yuan, a year-on-year increase of 0.4%; the Net income attributable to the parent company is 0.733 billion yuan, a year-on-year increase of 2.6%, while the adjusted Net income attributable to the parent company is 1.018 billion yuan, a year-on-year increase of 41.6%. CICC's main views are as follows: steady growth throughout the year, with the share of Innovative Drugs revenue continuing to rise.
AbbVie Options Spot-On: On March 25th, 79,116 Contracts Were Traded, With 338.09K Open Interest
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
